Clinical trials
High-Risk Cancer clinical trials
Below are recruiting high-risk cancer clinical trials, each written for real people, not researchers. We’re tracking 396 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05116072RecruitingPhase 1/Phase 2
Islet cell transplant plus surgery for high fistula risk
This Phase 1/2 study tests whether adding an islet (insulin-producing cell) transplant at the time of pancreatic-region surgery is safe and helps prevent a serious surgical complication called a postoperative fistula. It is for people whose surgery is considered high risk for developing that complication.
LilleAges 18 years+ - NCT06210490RecruitingPhase 2
Antibody-drug combo with radiation for HER2+ UTUC after surgery
This trial tests a combination of an antibody-drug conjugate (Disitamab Vedotin) plus radiation therapy after surgery to prevent upper tract urothelial cancer from coming back. It is for patients with HER2-positive tumors and high-risk features who cannot receive cisplatin chemo.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06172296RecruitingPhase 3
Dinutuximab plus transplant for high-risk neuroblastoma
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
Birmingham, AlabamaAges Up to 30 years - NCT05414032RecruitingPhase 2
Using leftover DNA signals to guide treatment after head and neck cancer
This Phase 2 trial tests a drug strategy for people with locally advanced head and neck cancer linked to HPV status. It looks at “molecular residual disease” by measuring tumor DNA in blood and uses early response and tumor test results to see who may benefit.
TorontoAges 18 years+ - NCT07562503RecruitingPhase 2
Blood Test to Guide Colorectal Cancer Follow-Up Treatment
This trial tests whether a special blood test that detects cancer DNA can help doctors decide if you need additional chemotherapy after colorectal cancer surgery. The goal is to personalize treatment based on your individual risk rather than giving chemotherapy to everyone.
ShanghaiAges 18–80 - NCT07749924Recruiting
Watchful waiting vs. bladder chemotherapy for intermediate-risk bladder cancer
This study compares two approaches for people with intermediate-risk bladder cancer whose urine shows no signs of cancer after surgery. One group will be watched closely (active surveillance), while the other will receive chemotherapy directly into the bladder (intravesical chemotherapy). The goal is to see if surveillance alone can prevent unnecessary treatment while keeping the cancer controlled.
DaqingAges 18 years+ - NCT07230847Recruiting
Healing of drug-coated vs. standard stents in high-bleeding-risk patients
This trial compares two types of stents (a drug-coated stent and a standard drug-eluting stent) in people with acute coronary syndrome who also have a high risk of bleeding. It uses a special camera to look at how the artery heals one month after the stent is placed.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06930573RecruitingPhase 4
AK112 for high-risk liver cancer after surgery
This study tests a new drug called AK112 (a combination antibody targeting two proteins that help tumors grow) after surgery for liver cancer that has a high chance of returning. The goal is to see if it can prevent the cancer from coming back.
Zhengzhou, HenanAges 18–75 - NCT05893030Recruiting
Monitoring pain and sleep medicines to prevent complications after surgery
This study looks at whether closely monitoring opioid and sleep medicines during and after surgery can lower organ problems and death in older adults at high risk. If you qualify, your team will track how these medicines are given to help keep you safer in the postoperative period.
AmiensAges 75 years+ - NCT04290663RecruitingPhase 3
Radioiodine decision after thyroid surgery for intermediate-risk cancer
This study compares two approaches after thyroid surgery: giving radioactive iodine right away versus deciding based on follow-up test results. It aims to see which approach better helps people with intermediate-risk differentiated thyroid cancer.
Pointe à Pitre, GuadeloupeAges 18 years+ - NCT04945642Recruiting
Radiation combination therapy for intermediate to high-risk prostate cancer
This trial studies a combination of two radiation types—high-dose-rate brachytherapy and stereotactic body radiotherapy—to treat certain intermediate- to high-risk prostate cancers. It may help by aiming radiation closely at the prostate while also targeting the cancer from outside the body.
Los Angeles, CaliforniaAges 18 years+ - NCT07231627Recruiting
Using AI to improve prostate cancer detection from MRI
This trial tests whether an artificial intelligence (AI) program can help doctors decide when a prostate biopsy is needed. It is for men who have had a prostate MRI that shows either a low-risk (PIRADS 1-2) or uncertain (PIRADS 3) spot, along with a higher-than-normal PSA level. You may qualify if you have certain risk factors like a high PSA density, suspicious digital rectal exam, or family history of prostate cancer.
Little Rock, ArkansasAges 40 years+ - NCT06220435Recruiting
Radiation therapy for very high-risk localized prostate cancer
This trial tests radiation therapy for men with very high-risk prostate cancer that hasn't spread. It aims to see if targeting the tumor with radiation can help control the cancer in this highest risk group.
LundAges 18 years+ - NCT06087068RecruitingPhase 2
Thyroid hormone therapy after lobectomy for low-risk thyroid cancer
This trial is testing whether thyroid hormone replacement after surgery is safe for people with low-risk papillary thyroid cancer. It may help maintain normal hormone levels after part of the thyroid is removed.
Beijing, Beijing MunicipalityAges 1.5 years–70 years - NCT06725576Recruiting
Comparing microwave ablation vs. surgery for low-risk thyroid cancer
This study compares a less invasive procedure (microwave ablation) with traditional surgery for treating a small, low-risk papillary thyroid cancer. If you have a single, small tumor with certain low-risk gene changes, you might be able to avoid surgery and have a quicker recovery.
Guangzhou, GuangdongAges 18–70 - NCT06261190Enrolling by invitation
Active monitoring for low-risk thyroid cancer
This trial tests whether it is safe to avoid immediate surgery and instead monitor small thyroid cancers that are considered low-risk. If you join, doctors will check regularly to make sure the cancer does not grow or spread.
Goyang-siAges 18 years+ - NCT07300566Recruiting
Focal versus whole-gland radiation boost for localized prostate cancer
This trial compares two ways of giving a radiation boost (brachytherapy) to the prostate for men with localized prostate cancer. One method targets only the visible tumor, while the other treats the whole gland, and the study aims to see if the focal approach works as well with fewer side effects.
London, OntarioAges 18 years+ - NCT07046585Recruiting
Blood test for colon cancer screening
This trial tests a new blood test to screen for colorectal cancer in people at average risk. You would give a blood sample before your scheduled colonoscopy, and the results will be compared to the colonoscopy findings.
Austin, TexasAges 40 years+ - NCT07841236RecruitingPhase 2
Blood test-guided immunotherapy for MSI-high colon cancer
This trial tests whether using a simple blood test (ctDNA) can help guide treatment with immunotherapy drugs (PD-1 inhibitors) for people with a specific type of colon cancer (MSI-high/dMMR). The goal is to see if this approach can improve outcomes and reduce side effects compared to standard care.
ShanghaiAges 18–75 - NCT04900623RecruitingPhase 2
Using HPV blood test to guide treatment for HPV throat cancer
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
Boston, MassachusettsAges 22 years+ - NCT06582446RecruitingPhase 2
AI-Personalized Radiation for High-Risk Prostate Cancer
This trial tests a new way to plan prostate cancer treatment using artificial intelligence and advanced imaging. It’s for people with high-risk prostate cancer that hasn’t spread to lymph nodes or other parts of the body, and who have not had prior radiation to the prostate.
LimassolAges 18 years+ - NCT00913939Recruiting
MRI-guided high-dose-rate treatment for recurrent prostate cancer
This study tests a targeted radiation approach called high-dose-rate (HDR) brachytherapy, guided by MRI, for certain people with recurrent or higher-risk prostate cancer. It may help deliver radiation more precisely, depending on your cancer type and prior treatments.
Toronto, OntarioAges 18 years+ - NCT06711055Recruiting
Taxane plus targeted therapy for early HER2-positive breast cancer
This trial tests a taxane chemotherapy combined with a targeted therapy for women with early-stage, HER2-positive breast cancer that has not spread to lymph nodes. It aims to provide a tailored treatment based on tumor size and risk factors.
Beijing, Beijing MunicipalityAges Any age - NCT06711068Recruiting
Chemotherapy plus targeted therapy for HER2+ early breast cancer
This trial tests whether adding targeted therapy to chemotherapy after surgery can help prevent HER2-positive early breast cancer from coming back. It is for patients whose cancer has not spread to lymph nodes and who have certain tumor sizes and features.
Beijing, Beijing MunicipalityAges Any age
Hear when a new High-Risk Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high-risk cancer?
- Yes. Clin2 currently lists 396 recruiting high-risk cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high-risk cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high-risk cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.